PT  - JOURNAL ARTICLE
AU  - Silva, Valéria Oliveira
AU  - de Oliveira, Elaine Lopes
AU  - Castejon, Marcia Jorge
AU  - Yamashiro, Rosemeire
AU  - Ahagon, Cintia Mayumi
AU  - López-Lopes, Giselle Ibette
AU  - da Silveira, Edilene Peres Real
AU  - Hong, Marisa Ailin
AU  - Carmo Timenetsky, Maria do
AU  - Freitas, Carmem Aparecida
AU  - Brígido, Luís Fernando de Macedo
TI  - Prevalence of antibodies against sars-cov-2 in professionals of a public health laboratory at são paulo, sp, brazil
AID  - 10.1101/2020.10.19.20213421
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.19.20213421
4099  - http://medrxiv.org/content/early/2020/10/21/2020.10.19.20213421.short
4100  - http://medrxiv.org/content/early/2020/10/21/2020.10.19.20213421.full
AB  - Background Covid-19 Serology may document exposure and perhaps protection to the virus and serological test may help understand epidemic dynamics. We tested health workers form a public laboratory to evaluate previous exposure to the virus and estimate the prevalence of antibodies against-SARS-CoV-2 in Adolfo Lutz Institute, State of São Paulo, Brazil.Methods This study was an open, prospective evaluation among professionals of Adolfo Lutz Institute some administrative personnel from the Secretary of Health that shares common areas with the institute. We used a lateral flow immunoassay (rapid test) to detect IgG and IgM for SARS-CoV-2; positive samples were further evaluated using Roche Electrochemiluminescence assay. SARS-CoV-2 RNA by real time reverse transcriptase polymerase chain reaction (RT-PCR) was also offered to participants.Results A total of 406 HPs participated. Thirty five (8.6%) tested positive on rapid test and 32 these rapid test seropositive cases were confirmed by ECLIA. 43 HPs had SARS-CoV-2 RNA detected at a median of 33 days, and the three cases not reactive at Roche ECLIA had a previous positive RNA. Outsourced professionals (34% seropositive), males (15%) workers referring COVID-19 patients at home (22%) and those living farther form the institute tended to have higher prevalence of seropositivity, but in multivariable logistic analysis only outsourced workers and those with COVID patients at home remained independently associated to seropositivity. We observed no relation of seropositivity to COVID samples handling. Presence of at least one symptom was common but some clinical manifestations as anosmia/dysgeusia. Fatigue, cough and fever were associated to seropositivity.Conclusions We documented a relatively high (8.6%) of anti-SARS-CoV-2 serological reactivity in this population, higher among outsourced workers and those residing with COVID-19 patients. COVID related work did not increased seropositivity. Some symptoms show strong association to COVID-19 serology and may be used in scoring tools for screening or diagnosis in resort limited settings.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialAlthough data was obtained within Institutional research protocols, tests were available to all workers as support for COVID-19 diagnosis Funding StatementFunding sources: No external funding was available for this work Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval - CEP IAL CAAE : 31924420.8.0000.0059 Institucional Scientific committe approval CTC 18M/2020All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available in COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxivThe data that support the findings of this study are openly available in COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv